21.95
+1.72(+8.50%)
Currency In USD
| Previous Close | 20.23 |
| Open | 20.97 |
| Day High | 22.18 |
| Day Low | 20.31 |
| 52-Week High | 26.25 |
| 52-Week Low | 5.83 |
| Volume | 338,322 |
| Average Volume | 191,267 |
| Market Cap | 924.32M |
| PE | -1.79 |
| EPS | -12.29 |
| Moving Average 50 Days | 15.94 |
| Moving Average 200 Days | 10.75 |
| Change | 1.72 |
If you invested $1000 in ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) since IPO date, it would be worth $1,221.48 as of September 16, 2025 at a share price of $21.95. Whereas If you bought $1000 worth of ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) shares 1 year ago, it would be worth $1,221.48 as of September 16, 2025 at a share price of $21.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
GlobeNewswire Inc.
Sep 02, 2025 11:05 AM GMT
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for th
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:05 AM GMT
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformat
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 20, 2025 8:15 PM GMT
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies f